Maggie L. Shaw

Several measures of hemodynamic capacity were improved in this study that evaluated sacubitril/valsartan use for heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH).

This new study investigated the impact of overly restrictive salt-intake guidelines on patients living with heart failure with preserved ejection fraction (HFpEF), because despite accounting for half of all HF cases, this patient population is often excluded from studies in the space.

Three methods of cosmetic surgery—local skin flap, full thickness skin graft, and secondary intention—were evaluated for their scarring risk following Mohs microscopic surgery on the distal third of the nose.

Anne McCall, PhD, provost and senior vice president for academic affairs at Xavier University of Louisiana, in New Orleans, delves into the new partnership between the university and Takeda.

New date from the KEYNOTE-716 trial show distant metastasis-free survival benefit from pembrolizumab use in melanoma.

Conflicting prior study results on the effectiveness of calprotectin expression as a protective or pathologic response among persons with chronic rhinosinusitis with nasal polyps (CRSwNP) spurred this new investigation.

A Belgian study compared exercise performance before and after COVID-19 lockdown measures were swiftly implemented in the country among patients with preexisting pulmonary arterial hypertension (PAH).

Although approved for use among patients with severe or refractory asthma, few studies have investigated its effectiveness among patients with comorbid mild to moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

Few data exist on how right ventricular fractional area change (RVFAC) may contribute to outcomes among patients hospitalized for heart failure, so that potential relationship was investigated in this new study from Japan.

Abstracts presented at this year's American Society of Clinical Oncology Annual meeting detailed the financial hardships many patients with cancer face, including those related to high-deductible health plans and clinical trial participation.

Investigators from Ghana evaluated cardiac abnormalities among persons living with HIV who were or were not on highly active antiretroviral treatment.

Knowing that insulin requirements vary widely among persons who have type 1 diabetes, 3-month effectiveness of the Omnipod 5 Automated Insulin Delivery System was evaluated across 6 daily insulin doses.

Using chronotropic response as a reference, study authors from Japan investigated the potential influence of exercise-induced heart rate on cardiac output reserve and exercise capacity among a cohort of patients with heart failure with preserved ejection fraction (HFpEF).

Investigators from Toronto compared morbidity and mortality outcomes among patients with acute decompensated heart failure (ADHF) before and during the COVID-19 pandemic.

Patients with iCCA, particularly those whose disease progresses following first-line chemotherapy, have limited overall treatment options. Data presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting show that patients may soon have a new agent to fight this rare cancer in futibatinib (Taiho Oncology), an FGFR inhibitor.

Will Nutland, DrPH, is cofounder of PrEPster, honorary assistant professor at the London School of Hygiene and Tropical Medicine, and an activist.

Extended safety and effectiveness of the Omnipod 5 AID system were investigated in this 12-month extension of a previous 3-month study conducted among persons living with type 1 diabetes (T1D).

In response to the Supreme Court last week overturning the landmark 1973 Roe v Wade decision, after previously upholding the constitutional right to an abortion in Planned Parenthood of Southeastern Pennsylvania v Casey, HHS Secretary Xavier Becerra outlined the next steps for the Biden administration.

A possible connection between integrase strand-transfer inhibitor (INSTI) use for HIV and cardiovascular disease (CVD) was investigated in this new study from an international team wanting more knowledge on the drug class’s treatment effects.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses the path of telemedicine reimbursement during the pandemic and possible ways it will change after the pandemic.

Using the Nationwide Inpatient Database for trends studied between 1993 and 2011, investigators from Columbia University Irving Medical Center evaluated hospitalization outcomes among patients with heart failure and comorbid gout.

The findings of this study, which used insurance claims data for patients 2 years and older to determine rates of meningococcal A, C, W, Y vaccine uptake, points to the need for more education, the authors said.

In this study, Italian investigators evaluated how sacubitril/valsartan (Sac/Val) dose titration among older patients with heart failure with reduced ejection fraction (HFrEF) might affect reverse cardiac remodeling and if the success of up-titration can be predicted.

Investigators from the Pediatric Diabetes Center at Hassenfeld Children’s Hospital at NYU Langone investigated outcomes disparities as they related to diabetes technology use among youth living with type 1 diabetes (T1D).

Bruce House in Ottawa, Ontario, Canada, has been serving individuals living with HIV and AIDS for 34-plus years. Here we speak with Patrick Morley, office and communications coordinator.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how enhancements to telemedicine precipitated by the COVID-19 pandemic have made lasting and meaningful changes to oncology care, including that these care improvements will persist post pandemic.

Outcomes in this new study, conducted among patients with chronic heart failure (CHF) on maintenance dialysis and receiving sacubitril/valsartan, were evaluated as they pertained to heart function and blood pressure.

The primary outcomes of this secondary analysis of the MOTIVATE-HF study were improvement in caregiver self-efficacy while caring for patients living with heart failure and caregiver contributions to self-care for these patients following motivational interviewing.

Hope S. Rugo, MD, FASCO, is professor of medicine and the director of the Breast Oncology and Clinical Trials Education program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She discusses her experience with palbociclib and letrozole in advanced breast cancer.

The new trial was the first to investigate outcomes among a patient population living with HIV (PLWH) who were treated for anal precancerous growths, or high-grade squamous intraepithelial lesions.